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ABSTRACT
THE INFLUENCE OF A SINGLE NUCLEOTIDE POLYMORPHISM IN THE MATRIX
METALLOPROTEINASE-1 PROMOTER ON GLIOMA BIOLOGY
Jessica McCready
A dissertation submitted in partial fulfillment of the requirements for ,the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2006
Director: Helen L. Fillmore, Ph.D. Assistant Professor Department of Neurosurgery,
Adjunct Assistant Professor Department of Anatomy and Neurobiology
Glioblastomas are an incurable type of brain tumor with a mean survival time of
9-12 months following diagnosis. One of the reasons for this poor prognosis is the
ability of tumor cells to invade the surrounding normal brain tissue.

Enzymes

responsible for this invasive nature include the matrix metalloproteinase family. MMP1 is a member of this family which has been well studied in many types of invasive
,tumors, with gliomas being an exception.

We studied a single nucleotide

polymorphism (SNP) in the MMP-1 promoter that may influence glioma biology. This
SNP consists of the presence (2G) or absence (1G) of a guanine nucleotide at position
-1607. The additional guanine nucleotide creates a binding site for ETS transcription
factors and combined with the AP-1 binding site at position -1602 creates a Ras
Responsive Element. We determined that the distribution of the MMP-1 genotype
differed significantly between the healthy population and the glioblastoma patient
population, with the 2G/2G genotype more prevalent in the glioblastoma patients.

In

addition, MMP-1 mRNA and protein examined in a select group of patient tissue had
significantly higher levels when compared to normal brain controls, however, there was
no correlation with genotype. Promoter reporter assays indicated that the 2G promoter

was approximately three times more active than the 1G promoter in three different
glioma cell lines.
We investigated potential signaling mechanisms responsible for increases in
MMP-1 transcription due to the presence of the RAS responsive element. Treatment
of glioma cell lines with hepatocyte growth factorlscatter factor (HGFISF) led to
significant increases in MMP-1 transcription, via the MAP kinase ERK pathway. AP-1
transcription factor proteins, cJun and cFos were increased in response to HGF
treatment but not Ets-1 and ETV-1. HGFISF treatment of glioma cell lines differing in
their MMP-1 genotype affected binding of ETS and AP-1 proteins to the endogenous
MMP-1 distal promoter. Using chromatin immunoprecipitation assays, we identified
these differentially DNA-bound AP-1 and ETS proteins.
The data presented indicate that the MMP-1 SNP (-1607) is important in glioma
biology and may contribute to tumor function and future investigations into its role in
glioma biology is warranted.

Chapter 1
Introduction

1.1 Brain Tumors
1.1.1 Overview of Brain Tumors
This section will present a general overview of adult cancers, with a focus on
gliomas, which account for approximately 86% of all malignant brain tumors. These
include the astrocytoma, oligodendroglioma and glioblastoma. Malignant brain tumors
make up 2% of all cancers in adults. This number is much higher for children as brain
tumors are the second most common cancer and the most common solid tumor in
childhood1. The incidences of brain tumors in both children under the age of 14 and in
the elderly over the age of 702 are increasing and unfortunately these tumors, in most
cases, remain incurable.
In the general population of the United States, gliomas occur at a rate of 5-10
per 100,000~.The incidence of gliomas increases, as in other cancers, in individuals
older than 30 years of age. In general, males are more likely than females to have a
brain tumor, with a male to female ratio of 1.5:1.

Most brain tumors occur in the

supratentorial region of the brain, in the frontal, temporal or parietal lobes, specifically1.
Currently, little is known about the risk factors for gliomas. Many studies have been
conducted, investigating such items as cell phones or head trauma for possible roles in
the etiology of brain tumors, but none has been found to consistently associate with
their incidence. Gliomas are thought to arise as a result of an accumulation of genetic
alterations resulting in the ability of the cells to escape checkpoints designed to prevent
uncontrolled cell growth. Therefore any agent that damages DNA, such as a chemical,
physical or biological agent, can be considered to be a neurocarcinogen.

One

environmental agent that has been associated with increases in brain tumors in adults
is ionizing radiation used as a treatment for childhood tumors and leukemia'.

Appendix 1.i DNA-Protein Affinity Pull Down Assay Protocol

This assay determines the ability of proteins to bind to a piece of DNA
mimicking the MMP-1 promoter. Before beginning the assay we performed PCR to
prepare the double stranded biotin labeled probe. The primer sequences were as
follows:

forward

5'-

biotinCCCTCTTGAACTCACATGTTATG-3';

GCGTCAAGACTGATATCT-TACTC-3'.

reverse

5'-

The forward primer was aliquoted upon

receipt from the company and only thawed one time. This ensured that each PCR
began with a fresh aliquot of biotinylated primer. We used 100 ng of genomic DNA
isolated from either T98 glioma cells (1G probe) or U251 glioma cells (2G probe). The
PCR conditions were as follows: 0.6 pM each primer, 200 pM dNTPs, 1.5 mM MgCI2,
1x PCR Buffer wlo MgCI2, 1 unit Platinum Taq in a total volume of 25 pL. The PCR
annealing temperature was 62°C and there were a total of 35 cycles. The PCR product
was run on a 2% agarose gel to ensure the expected size piece of 11Obp. The product
must be purified by ethanol precipitation and resuspended in 60pL of TE pH 8.0. The
purified probe was run on an agarose gel to quantify the amount relative to the DNA
ladder. Two rounds of PCR were necessary to obtain enough probe for the assay.
2 x 1o6 U251 cells were plated in 10 % DMEM. 24 hours post plating the cells
were rinsed with PBS and starved from serum overnight. 30nglmL of HGF was added
to 3 mLs of fresh serum free media the following morning. At the desired timepoint the
media was removed from the plate, the plates were washed once with PBS and the
cells were scraped to the bottom of the plate and transferred to an eppendorf tube with
1.5 mL ice cold PBS. Samples were spun for 10 minutes at maximum speed in a table
top centrifuge at 4" C. The cell pellet was either used immediately or frozen at -80°C

for use in the future. Nuclei were extracted following the method described in chapter
2 of this document and nuclear lysates were quantitated with the Coomassie Plus
Protein Assay. 60-100 pg of nuclear protein was added to an eppendorf tube to a final
volume of 500 pL Lysis Buffer (20 mM HEPES, 10% glycerol, 50mM KCL, 0.2 mM
EDTA, 1.5 mM MgCI2, 20 pM ZnC12, 1 mM DTT, and 0.25% Triton X-100). Protease
and phosphatase inhibitors were added just before use.

Nuclear extract was

precleared with 20 pL Streptavidin-Paramagentic particles (SA-PMP, Pierce) in a
rotating wheel at 4°C. [The SA-PMPs must be washed three times with 1 mL lysis
buffer and collected in a magnetic stand 15 minutes prior to use.] Following the preclearing step the SA-PMPs were recovered in a magnetic stand.

1pg of the

biotinylated oligonucleotide and 4 pg testes DNA were added to the pre-cleared
supernatant and allowed to rotate at 4°C for 30 minutes after which 20 pL of washed
SA-PMPs was added and the samples continued rotating for 2 hours at 4°C. The SAPMP-DNA complexes were washed three times with 1 mL lysis buffer. After each
wash the supernatant was discarded. After the final wash, 20 pL of Laemmli Sample
Buffer:BME (950:50) was added to each sample. The samples were boiled for 5
minutes and loaded into a Tris-Gly Gel (Invitrogen). The gel was run at 125 V for two
hours and transferred at 25 V for two hours.

probe 1G

2G

Appendix I.ii DNA-Protein Affinity Pull Down Assay cFos
The AP-1 protein cFos is able to bind to a biotinylated probe mimicking the 2G
promoter following HGFISF treatment for 5 hours. These results are in agreement with
the ChlP assay that also indicated that cFos bound to the endogenous 2G promoter at
5 hours. Results from the ChlP assay also suggest that cFos is bound to the 1G
promoter. There is a slight band in both the 5 hour and 12 hour lane that may
correspond to cFos bound to the 1G promoter.

T98

U87
Labeled MMP-1 probe
10pgnuclearextract
1Ox cold MMP-1 probe
10xcoldEts-lprobe
cold NFkB pr

+ + +

+I-

-

+ + + + - + + +

- - -

- +

+

- - - - -

LN-Z308
+I I + + + + + I
+ - + + + +

- - - - + - - -

+

+ - - + -

Appendix I.iv Electromobility Shift Assay -- 1G probe
We performed an EMSA with a double stranded radionucleotide labeled probe
mimicking the distal 1G MMP-1 promoter to determine if there was a difference in the
banding pattern between the 1G and the 2G promoter probes. The data seems to
suggest that there are similar proteins bound to both promoters however further
experiments would be needed to confirm this initial observation.

Labeled MMP-1 probe
10pgnuclearextract
10x cold MMP-1 probe
10x cold NFkB probe
Ets-1 Supershift
Ets-2 Supershift
Rabbit IgG

I+ + + + + + +I
- + + + + + +
- - + - - - -

- - - + - - - - - - + - - - - - + -

Appendix I.iii Electromobility Shift Assay - Supershift.
We performed an EMSA with antibodies to both Ets-1 and Ets-2 to determine if these
are possible proteins bound to a probe mimicking the distal 2G promoter. Neither
antibody formed a complex with the DNA-probe complex as indicated by the lack of a
supershift of the band shift. This does not rule out these proteins as candidates of
proteins bound to the probe because it could be a limitation of the antibody that is
interfering with the protein-DNA-probe complex formation.

Appendix 1l.i Promoter Activation 1G Promoter -/+ HGFISF
We peformed a luciferase reporter assay with the full length MMP-1 1G promoter
construct (obtained from Constance Brinckerhoff, PhD) to determine the response of
the 1G promter to HGFISF treatment in glioma cells. The 1G promoter responds to the
HGFISF beginning at approximately three hours and continues at least for 24 hours. It
is not surprising that the 1G promoter responds to HGFISF since it contains many
binding sites that may be responsive to the growth factor including the necessary ETS
element located at position -87 in the proximal promoter.

Appendix Il.ii Promoter Activation 2G Promoter -I+ HGFISF
We peformed a luciferase reporter assay with the full length MMP-1 2G promoter
construct (obtained from Constance Brinckerhoff, PhD) to determine the response of
the 2G promter to HGFISF treatment in glioma cells. The peak of 2G promoter ac.tivity
is 12 hours after HGFISF treatment but the promoter activity begins at three hours in
response to the growth factor and continues for at least 24 hours.
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